Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab

[...]omalizumab prevents IgE from binding to mast cells and basophils but should not inhibit direct effects of IgE produced by binding to BP180 on the surface of keratinocytes. [...]if IgG and IgE both play a role in BP lesion development, the remaining IgG may be responsible for the residual diseas...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 123; no. 3; pp. 704 - 705
Main Authors Fairley, Janet A., MD, Baum, Christian L., MD, Brandt, Debra S., BSN, Messingham, Kelly A.N., PhD
Format Journal Article
LanguageEnglish
Published United States Mosby, Inc 01.03.2009
Elsevier Limited
Subjects
Aged
Allergy and Immunology
Anti-Allergic Agents - therapeutic use
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Asthma
Autoantibodies - blood
Autoantibodies - immunology
Autoantigens - immunology
Autoantigens - metabolism
Autoimmune diseases
Autoimmunity - immunology
Collagen Type XVII
Disease
Female
Humans
Immunoglobulin E - blood
Immunoglobulin E - immunology
Non-Fibrillar Collagens - immunology
Non-Fibrillar Collagens - metabolism
Omalizumab
Patients
Pemphigoid, Bullous - drug therapy
Pemphigoid, Bullous - immunology
Pemphigoid, Bullous - pathology
Studies
Online AccessGet full text

Cover

More Information
Summary:[...]omalizumab prevents IgE from binding to mast cells and basophils but should not inhibit direct effects of IgE produced by binding to BP180 on the surface of keratinocytes. [...]if IgG and IgE both play a role in BP lesion development, the remaining IgG may be responsible for the residual disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.11.035